Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript February 19, 2026Praxis Precision Medicines, Inc. misses on earnings expectations.
Praxis Precision Medicines Inc. (PRAX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 1,995,986 | $588,296,914 | +28% | 10.49% |
| 2. | Orbis Investment Management William B. Gray | 1,255,162 | $369,946,448 | 1.55% | |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,126,488 | $332,021,073 | +64% | 1.94% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 965,313 | $284,516,354 | -60% | 0.43% |
| 5. | Cormorant Asset Management Bihua Chen | 950,000 | $280,003,000 | -5% | 12.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.75 | 14,500 | $25,375.00 | 14,500 | 2023-10-05 | Filing | |
| $1.06 | 10,000 | $10,587.00 | 45,002 | 2023-06-27 | Filing | |
| $0.87 | 8,000 | $6,997.60 | 46,416 | 2023-03-24 | Filing | |
| $0.86 | 35,002 | $30,206.51 | 35,002 | 2023-03-23 | Filing | |
| $0.86 | 35,000 | $30,159.50 | 226,299 | 2023-03-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $194.30 | 9,100 | $1,768,130.00 | 20,832 | 2025-11-20 | Filing | |
| $193.23 | 977 | $188,788.64 | 29,932 | 2025-11-20 | Filing | |
| $192.53 | 13,339 | $2,568,197.69 | 30,909 | 2025-11-20 | Filing | |
| $190.86 | 1,714 | $327,139.18 | 44,248 | 2025-11-20 | Filing | |
| $192.71 | 2,145 | $413,365.10 | 10,442 | 2025-11-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,240,086 | $954,833,974 | 0.43% | |
| 2. | 2,078,500 | $612,617,092 | 0.01% | |
| 3. | 1,460,933 | $430,595,392 | 0.01% | |
| 4. | 1,358,675 | $400,455,884 | 0.02% | |
| 5. | 889,889 | $262,286,289 | 0.02% |
News See All
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best stocks to buy and hold for the next 6 months. On February 10, Guggenheim raised its price target for Praxis Precision Medicines Inc.
Wells Fargo Cautious on Praxis Precision (PRAX) After Recent Revenue Estimates
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 13 hot stocks to buy with the highest upside potential.
10 Best Stocks to Buy and Hold for the Next 6 Months
Investors are becoming more selective toward tech stocks amid valuation concerns, with the overall market at all-time highs.
Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)
On February 10, Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines (NASDAQ:PRAX) from $760 to $800.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800
Guggenheim, on February 10, raised its target price on Praxis Precision (PRAX) by 5.3% to $800 (from $760) and reiterated its Buy recommendation on the stock.
13 High-Risk High-Reward Growth Stocks to Invest In
“Will the US Fed cut rates?” seems to be the question everyone is asking after the release of the January US jobs report on February 11, which showed a stronger-than-expected labor market.
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus
On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company’s recent public offering as the basis for the adjustment.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Hedge Fund Resource Center